SLG
ALBO

Stanley-Laman Group’s Albireo Pharma Inc ALBO Stock Holding History

Stanley-Laman Group’s Portfolio ALBO Stock Details ALBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-32,788
Closed -$1.08M – 304
2018
Q3 		$1.08M Buy
+32,788
New +$1.07M 0.27% 118

Other funds holding ALBO

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return

Stanley-Laman Group's ALBO Position: Q4 2018 in Review

Stanley-Laman Group sold out of Albireo Pharma Inc (ALBO) in Q4 2018, closing a stake of 32,788 shares — an estimated $1.08M sold.

Stanley-Laman Group first reported a position in ALBO in Q3 2018 and held it in 1 quarter. The position peaked at $1.08M in Q3 2018. 68 funds tracked by Wall St. Rank hold ALBO as of Q4 2018.

  • Stanley-Laman Group reported no remaining Albireo Pharma Inc position as of Q4 2018 after selling out during the quarter.
  • Stanley-Laman Group sold 32,788 Albireo Pharma Inc shares in Q4 2018, an estimated $1.08M.
  • Stanley-Laman Group first reported a position in Albireo Pharma Inc in Q3 2018 and held it in 1 quarter.
  • Stanley-Laman Group's Albireo Pharma Inc position peaked at $1.08M in Q3 2018.
  • 68 funds tracked by Wall St. Rank held Albireo Pharma Inc as of Q4 2018.

Based on Stanley-Laman Group's 13F filing for Q4 2018, filed 7 Feb 2019.